Current report no.: 22/2023
Date of preparation: August 24, 2023.
Legal basis: Article 17 par. 1 of the MAR Regulation – confidential information.
The Management Board of Medicalgorithmics S.A. headquartered in Warsaw (“Company”) informs about the publication on August 23, 2023 for its subsidiary, Kardiolytics Inc. (“Cardiolytics”), two European patents with the following numbers: EP 3 726 460 B1 and EP 3719 744 B1. The Company received today (August 24, 2023) a notification of the patents’ publication. Patent protection is granted after completing additional formalities, in particular validating patents.
The patent EP3726460 involves a method for autonomously segmenting contrast-filled coronary artery vessels in computed tomography (CT) images. This technology focuses on automating the process of identifying and delineating coronary artery vessels that have been enhanced with contrast material. This innovation could improve the efficiency and accuracy of identifying coronary artery structures in medical imaging, potentially aiding in the diagnosis and treatment of cardiovascular conditions.
The patent EP3719744 presents a method and system that employ machine learning for segmenting contrast-filled coronary artery vessels in medical images. This technology focuses on using advanced algorithms to automatically identify and delineate coronary artery structures that have been enhanced with contrast material. This innovation aims to enhance the accuracy and efficiency of identifying coronary arteries in medical imaging, potentially assisting in the diagnosis and management of cardiovascular conditions.
These are further patents obtained by Kardiolytics. Securing innovation and technology patents will enable Kardiolytics to promote and commercialize its inventions, including technology supporting computerized coronary artery diagnostics. Most importantly, it will help protect Kardiolytics’ unique intellectual property, enabling further development of the solution and improving CAD (Coronary Artery Disease) diagnostics.
Kardiolytics, a company that develops solutions for medicine based on artificial intelligence, joined the Medicalgorithmics Group in November 2022.
The Issuer publishes this information as it illustrates the development of technology for computer-assisted diagnosis and treatment of coronary artery disease by Kardiolytics Inc.